On April 29, 2010
Prostate Cancer Vaccine Provenge Faces Toughest Test Yet: The Real World
The FDA’s approval of Dendreon (DNDN)’s Provenge vaccine for prostate cancer (pictured) sweeps away past doubts about the company — over the quality of its data and whether there was a conspiracy to manipulate its stock — but brings the
…
0 Comments